ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 150 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $246,645 | -52.2% | 22,081 | -8.4% | 0.00% | -100.0% |
| Q2 2023 | $515,890 | -48.5% | 24,107 | -2.7% | 0.00% | 0.0% |
| Q1 2023 | $1,001,497 | -13.8% | 24,765 | -0.9% | 0.00% | -50.0% |
| Q4 2022 | $1,162,209 | -9.1% | 24,983 | +1.3% | 0.00% | 0.0% |
| Q3 2022 | $1,279,000 | +8.3% | 24,666 | -1.3% | 0.00% | 0.0% |
| Q2 2022 | $1,181,000 | -30.8% | 24,986 | +4.2% | 0.00% | 0.0% |
| Q1 2022 | $1,707,000 | -11.4% | 23,981 | -6.9% | 0.00% | 0.0% |
| Q4 2021 | $1,927,000 | +34.2% | 25,771 | +1.9% | 0.00% | 0.0% |
| Q3 2021 | $1,436,000 | +22.4% | 25,284 | -5.1% | 0.00% | +100.0% |
| Q2 2021 | $1,173,000 | -17.2% | 26,655 | -7.2% | 0.00% | -50.0% |
| Q1 2021 | $1,416,000 | +17.1% | 28,716 | +0.0% | 0.00% | 0.0% |
| Q4 2020 | $1,209,000 | -8.7% | 28,708 | -0.7% | 0.00% | 0.0% |
| Q3 2020 | $1,324,000 | -8.8% | 28,921 | 0.0% | 0.00% | -33.3% |
| Q2 2020 | $1,452,000 | -2.4% | 28,921 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $1,487,000 | -7.6% | 28,921 | +10.9% | 0.00% | 0.0% |
| Q4 2019 | $1,610,000 | +0.2% | 26,068 | -2.5% | 0.00% | 0.0% |
| Q3 2019 | $1,606,000 | -27.9% | 26,738 | +1.2% | 0.00% | -25.0% |
| Q2 2019 | $2,229,000 | -9.0% | 26,419 | +3.0% | 0.00% | -20.0% |
| Q1 2019 | $2,450,000 | +32.1% | 25,650 | -2.0% | 0.01% | +25.0% |
| Q4 2018 | $1,855,000 | -15.3% | 26,185 | +2.2% | 0.00% | 0.0% |
| Q3 2018 | $2,189,000 | -26.3% | 25,612 | -0.1% | 0.00% | -33.3% |
| Q2 2018 | $2,971,000 | +55.4% | 25,638 | +8.5% | 0.01% | +50.0% |
| Q1 2018 | $1,912,000 | +33.1% | 23,636 | -3.4% | 0.00% | +33.3% |
| Q4 2017 | $1,436,000 | +23.4% | 24,464 | -1.7% | 0.00% | 0.0% |
| Q3 2017 | $1,164,000 | +17.5% | 24,882 | -9.7% | 0.00% | +50.0% |
| Q2 2017 | $991,000 | +4.6% | 27,541 | -10.4% | 0.00% | 0.0% |
| Q1 2017 | $947,000 | -12.3% | 30,741 | -4.7% | 0.00% | 0.0% |
| Q4 2016 | $1,080,000 | +22.9% | 32,241 | -2.4% | 0.00% | 0.0% |
| Q3 2016 | $879,000 | +21.7% | 33,041 | +0.9% | 0.00% | 0.0% |
| Q2 2016 | $722,000 | -27.6% | 32,741 | -3.5% | 0.00% | 0.0% |
| Q1 2016 | $997,000 | +1.8% | 33,945 | +14.5% | 0.00% | 0.0% |
| Q4 2015 | $979,000 | -7.4% | 29,643 | +1.4% | 0.00% | -33.3% |
| Q3 2015 | $1,057,000 | -19.6% | 29,238 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $1,315,000 | +127.9% | 29,238 | +55.2% | 0.00% | +200.0% |
| Q1 2015 | $577,000 | -40.7% | 18,833 | -1.6% | 0.00% | -50.0% |
| Q4 2014 | $973,000 | +29.0% | 19,133 | +0.4% | 0.00% | 0.0% |
| Q3 2014 | $754,000 | -7.1% | 19,051 | +1.1% | 0.00% | 0.0% |
| Q2 2014 | $812,000 | +209.9% | 18,843 | +188.0% | 0.00% | +100.0% |
| Q1 2014 | $262,000 | +47.2% | 6,543 | 0.0% | 0.00% | – |
| Q4 2013 | $178,000 | +18.7% | 6,543 | 0.0% | 0.00% | – |
| Q3 2013 | $150,000 | +33.9% | 6,543 | +3.2% | 0.00% | – |
| Q2 2013 | $112,000 | – | 6,343 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
| Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
| ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
| Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
| Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
| Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
| Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
| Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |